Brokerages Set Cognition Therapeutics, Inc. (NASDAQ:CGTX) PT at $8.30

Cognition Therapeutics, Inc. (NASDAQ:CGTX) has received an average recommendation of “Moderate Buy” from the six brokerages that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $8.30.

A number of research analysts recently weighed in on CGTX shares. Chardan Capital reaffirmed a “buy” rating and issued a $11.00 price target on shares of Cognition Therapeutics in a research note on Thursday, December 19th. HC Wainwright lifted their price target on Cognition Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a research note on Thursday, December 19th. Finally, B. Riley raised Cognition Therapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the company from $1.00 to $1.50 in a research note on Thursday, December 19th.

Institutional Investors Weigh In On Cognition Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CGTX. Virtu Financial LLC acquired a new position in shares of Cognition Therapeutics in the third quarter valued at approximately $27,000. CM Management LLC raised its stake in Cognition Therapeutics by 14.3% in the second quarter. CM Management LLC now owns 200,000 shares of the company’s stock valued at $332,000 after buying an additional 25,000 shares in the last quarter. Mercer Global Advisors Inc. ADV lifted its stake in Cognition Therapeutics by 33.4% during the second quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock worth $159,000 after purchasing an additional 24,050 shares during the last quarter. Finally, Sigma Planning Corp lifted its position in shares of Cognition Therapeutics by 14.6% during the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock worth $92,000 after buying an additional 25,050 shares during the last quarter. Institutional investors and hedge funds own 43.35% of the company’s stock.

Cognition Therapeutics Stock Down 10.7 %

CGTX opened at $0.75 on Tuesday. The company has a market cap of $31.16 million, a price-to-earnings ratio of -0.77 and a beta of 1.26. The firm’s fifty day simple moving average is $0.50 and its two-hundred day simple moving average is $0.87. Cognition Therapeutics has a 52-week low of $0.34 and a 52-week high of $2.95.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.